Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Pomalidomide:

Search results

Items: 1 to 20 of 391

  • Filters activated: Toxicology. Clear all to show 609 items.
1.

Analysis of exposure margins in developmental toxicity studies for detection of human teratogens.

Andrews PA, Blanset D, Costa PL, Green M, Green ML, Jacobs A, Kadaba R, Lebron JA, Mattson B, McNerney ME, Minck D, Oliveira LC, Theunissen PT, DeGeorge JJ.

Regul Toxicol Pharmacol. 2019 Apr 11;105:62-68. doi: 10.1016/j.yrtph.2019.04.005. [Epub ahead of print]

PMID:
30981719
2.

A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Mikhael J, Richardson P, Usmani SZ, Raje N, Bensinger W, Karanes C, Campana F, Kanagavel D, Dubin F, Liu Q, Semiond D, Anderson K.

Blood. 2019 Mar 12. pii: blood-2019-02-895193. doi: 10.1182/blood-2019-02-895193. [Epub ahead of print]

PMID:
30862646
3.

[Immunomodulator drugs for the treatment of multiple myeloma].

Fernández-Lázaro D, Fernández-Lázaro CI, Caballero García A, Córdova Martínez A.

Rev Med Chil. 2018 Dec;146(12):1444-1451. doi: 10.4067/s0034-98872018001201444. Review. Spanish.

4.

Thalidomide and Its Analogs Differentially Target Fibroblast Growth Factor Receptors: Thalidomide Suppresses FGFR Gene Expression while Pomalidomide Dampens FGFR2 Activity.

Sundaresan L, Kumar P, Manivannan J, Balaguru UM, Kasiviswanathan D, Veeriah V, Anishetty S, Chatterjee S.

Chem Res Toxicol. 2019 Apr 15;32(4):589-602. doi: 10.1021/acs.chemrestox.8b00286. Epub 2019 Mar 15.

PMID:
30834740
5.

PROTAC-mediated crosstalk between E3 ligases.

Steinebach C, Kehm H, Lindner S, Vu LP, Köpff S, López Mármol Á, Weiler C, Wagner KG, Reichenzeller M, Krönke J, Gütschow M.

Chem Commun (Camb). 2019 Feb 5;55(12):1821-1824. doi: 10.1039/c8cc09541h.

PMID:
30672516
6.

Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients.

Giralt S, Seifter E.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):103-109. doi: 10.1182/asheducation-2018.1.103. Review.

PMID:
30504298
7.

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J.

N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.

PMID:
30403938
8.

Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.

Sievers QL, Petzold G, Bunker RD, Renneville A, Słabicki M, Liddicoat BJ, Abdulrahman W, Mikkelsen T, Ebert BL, Thomä NH.

Science. 2018 Nov 2;362(6414). pii: eaat0572. doi: 10.1126/science.aat0572.

PMID:
30385546
9.

Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.

Xu XS, Dimopoulos MA, Sonneveld P, Ho PJ, Belch A, Leiba M, Capra M, Gomez D, Medvedova E, Iida S, Min CK, Schecter J, Jansson R, Zhang L, Sun YN, Clemens PL.

Adv Ther. 2018 Nov;35(11):1859-1872. doi: 10.1007/s12325-018-0815-9. Epub 2018 Oct 29.

10.

Pomalidomide Ameliorates H₂O₂-Induced Oxidative Stress Injury and Cell Death in Rat Primary Cortical Neuronal Cultures by Inducing Anti-Oxidative and Anti-Apoptosis Effects.

Tsai YR, Chang CF, Lai JH, Wu JC, Chen YH, Kang SJ, Hoffer BJ, Tweedie D, Luo W, Greig NH, Chiang YH, Chen KY.

Int J Mol Sci. 2018 Oct 19;19(10). pii: E3252. doi: 10.3390/ijms19103252.

11.

UBE2G1 governs the destruction of cereblon neomorphic substrates.

Lu G, Weng S, Matyskiela M, Zheng X, Fang W, Wood S, Surka C, Mizukoshi R, Lu CC, Mendy D, Jang IS, Wang K, Marella M, Couto S, Cathers B, Carmichael J, Chamberlain P, Rolfe M.

Elife. 2018 Sep 20;7. pii: e40958. doi: 10.7554/eLife.40958.

12.

Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules.

Mendez JS, Grommes C.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:604-615. doi: 10.1200/EDBK_200829. Review.

PMID:
30231317
13.

Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.

Chehab S, Panjic EH, Gleason C, Lonial S, Nooka AK.

Future Oncol. 2018 Dec;14(30):3111-3121. doi: 10.2217/fon-2018-0275. Epub 2018 Aug 23. Review.

PMID:
30136602
14.

Homo-PROTACs for the Chemical Knockdown of Cereblon.

Steinebach C, Lindner S, Udeshi ND, Mani DC, Kehm H, Köpff S, Carr SA, Gütschow M, Krönke J.

ACS Chem Biol. 2018 Sep 21;13(9):2771-2782. doi: 10.1021/acschembio.8b00693. Epub 2018 Sep 5.

PMID:
30118587
15.

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.

Sivaraj D, Green MM, Kang Y, Long GD, Rizzieri DA, Li Z, Garrett AH, McIntyre JL, Chao NJ, Gasparetto C.

Blood Cancer J. 2018 Jul 31;8(8):71. doi: 10.1038/s41408-018-0104-5. No abstract available.

16.

A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension.

Li Y, Liu L, Huang L, Wang X, Hoffmann M, Reyes J, Palmisano M, Zhou S.

Clin Pharmacol. 2018 Jul 19;10:89-99. doi: 10.2147/CPAA.S171735. eCollection 2018.

17.

Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide.

Oka S, Ono K, Nohgawa M.

J Clin Pharm Ther. 2018 Dec;43(6):914-917. doi: 10.1111/jcpt.12740. Epub 2018 Jul 4.

PMID:
29974481
18.

Novel Approaches for the Management of AL Amyloidosis.

Joseph NS, Kaufman JL.

Curr Hematol Malig Rep. 2018 Jun;13(3):212-219. doi: 10.1007/s11899-018-0450-1. Review.

PMID:
29951831
19.

Maintenance and continuous therapy for multiple myeloma.

Richardson PG, Laubach J, Gandolfi S, Facon T, Weisel K, O'Gorman P.

Expert Rev Anticancer Ther. 2018 Aug;18(8):751-764. doi: 10.1080/14737140.2018.1490181. Epub 2018 Jul 3. Review.

PMID:
29932776
20.

Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma.

Kinoshita S, Ri M, Kanamori T, Aoki S, Yoshida T, Narita T, Totani H, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S.

Oncol Lett. 2018 Jun;15(6):9450-9456. doi: 10.3892/ol.2018.8501. Epub 2018 Apr 16.

Supplemental Content

Loading ...
Support Center